Biotech Archives - Page 43 of 795

2 minute read

BioCryst Pharmaceuticals ‘Fantastic’ Q1 Earnings Rides On Outstanding Orladeyo Performance

May 6, 2:59 PM

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue

BCRX

1 minute read

Why Outset Medical Shares Are Up Today

By Erica Kollmann

May 6, 2:40 PM

Outset said that it has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States.

2 minute read

Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data

By Vandana Singh

May 6, 2:10 PM

Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NMIBC patients and TAR-200's promising outcomes for BCG-unresponsive cases.

JNJ

2 minute read

Hormel Foods Recalls Some Contaminated Planters Nuts In Five States

By Vandana Singh

May 6, 1:46 PM

Hormel Foods recalls Planters products due to listeria contamination. Details on impacted items & distribution areas.

HRL

2 minute read

Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide

By Vandana Singh

May 6, 1:17 PM

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

GOSS

4 minute read

Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo

By Benzinga Newsdesk

May 6, 11:18 AM

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events

ACHV

4 minute read

“Florida GOP Formally Opposes Marijuana Legalization Ballot Initiative, Clearing Path For DeSantis To Fund ‘Counter Message’ Campaign” – Marijuana Moment

By Benzinga Newsdesk

May 6, 10:54 AM

https://www.marijuanamoment.net/florida-gop-formally-opposes-marijuana-legalization-ballot-initiative-clearing-path-for-desantis-to-fund-counter-message-campaign/The Florida Republican Party has officially come out

ACB

3 minute read

On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk Non-Muscle-Invasi…

By Benzinga Newsdesk

May 6, 10:27 AM

Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterationsSAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson

JNJ

2 minute read

What’s Going With BioNTech Stock On Monday?

By Vandana Singh

May 6, 10:02 AM

BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves.

BNTX

2 minute read

Lexaria Announces New Research Program To Evaluate Mode Of Action And Performance Of DehydraTECH-GLP-1 Drugs

By Benzinga Newsdesk

May 6, 9:08 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of

LEXX